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Abstract
Background: Previous studies of predictors of end-stage renal disease (ESRD) have limitations: (1) some focused
on patients with clinically recognized chronic kidney disease (CKD); (2) others identified population-based patients
who developed ESRD, but lacked earlier baseline clinical measures to predict ESRD. Our study was designed to
address these limitations and to identify the strength and precision of characteristics that might predict ESRD
pragmatically for decision-makers–as measured by the onset of renal replacement therapy (RRT).
Methods: We conducted a population-based, retrospective case-control study of patients who developed ESRD
and started RRT. We conducted the study in a health maintenance organization, Kaiser Permanente Northwest
(KPNW). The case-control study was nested within the adult population of KPNW members who were enrolled
during 1999, the baseline period. Cases and their matched controls were identified from January 2000 through
December 2004. We evaluated baseline clinical characteristics measured during routine care by calculating the
adjusted odds ratios and their 95% confidence intervals after controlling for matching characteristics: age, sex, and
year.
Results: The rate of RRT in the cohort from which we sampled was 58 per 100,000 person-years (95% CI, 53 to 64).
After excluding patients with missing data, we analyzed 350 cases and 2,114 controls. We identified the following
characteristics that predicted ESRD with odds ratios ≥ 2.0: eGFR<60 mL/min/1.73 m
2 (OR = 20.5; 95% CI, 11.2 to
37.3), positive test for proteinuria (OR = 5.0; 95% CI, 3.5 to 7.1), hypertension (OR = 4.5; 95% CI, 2.5 to 8.0), gout/
positive test for uric acid (OR = 2.5; 95% CI, 1.8 to 3.5), peripheral vascular disease (OR = 2.2; 95% CI, 1.4 to 3.6),
congestive heart failure (OR = 2.1; 95% CI, 1.4 to 3.3), and diabetes (OR = 2.1; 95% CI, 1.5 to 2.9).
Conclusions: The clinical characteristics needed to predict ESRD–for example, to develop a population-based,
prognostic risk score–were often documented during routine care years before patients developed ESRD and
required RRT.
Background
The National Kidney Foundation’s( N K F )K i d n e yD i s -
ease Outcomes Quality Initiative (K/DOQI) encourages
providers to conduct laboratory screening of patients to
identify unrecognized chronic kidney disease (CKD) and
stratify patients into stages of CKD based on their
serum creatinine values–as an estimate of their glomer-
ular filtration rate (GFR)–so that providers can inter-
vene to slow the progression to end-stage renal disease
(ESRD) and other outcomes, such as cardiovascular
events and mortality[1]. The utility of the NKF guide-
lines is not limited to management of individual
patients. The guidelines offer an opportunity to manage
populations of patients, especially within large integrated
healthcare systems. The use of patient demographic
information, laboratory values, patient education, and
comprehensive supportive services can maximize the
impact of the NKF guidelines within a large population.
Population-based CKD management may reduce the
burden of CKD and prevent or delay patients’ progres-
sion to renal replacement therapy (RRT).
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tors for progression to ESRD identified patients on the
basis of elevated serum creatinine[2] or treatment with
renal replacement therapy[3] and asked participants to
recall their medical history with a focus on long-term
analgesic use. Interviewing does not work well for
detailed clinical characteristics, especially laboratory
values measured years earlier.
Investigators using data from Kaiser Permanente
Northern California conducted a cohort study among
177,570 patients who had participated in health screening
during 1964 and 1973 to evaluate a range of potential
baseline predictors of ESRD (as measured by RRT) dur-
ing a 25-year follow-up[4]. Their study provides a wealth
of explanatory insight into predictors, including some
that have only recently been recognized, such as lower
hemoglobin values and elevated serum uric acid levels.
Because their characteristics (predictors) were collected
according to a study protocol among consenting study
volunteers, and their hazard ratios reflect an induction
period of up to 25 years, decision-makers may still have
pragmatic questions about predictors collected during
routine care (without a protocol), among a broader spec-
trum of patients (without requiring consent for study
participation), over a briefer period. The same pragmatic
considerations hold for a large Japanese cohort study,
which collected data during the early 1980s [5].
Two ongoing prospective, observational studies mea-
sured detailed clinical characteristics at baseline and
continue to follow patients to predict a range of out-
comes, including ESRD[6,7]. Both CRIC and STRIDE
enrolled patients with known CKD who were identified
in the clinic-based setting. However, it’s unclear whether
either study will be sufficiently powered to identify mul-
tivariable predictors of ESRD because those analyses
depend on the number of events, not the number of
patients. That may be one reason why both CRIC and
STRIDE will evaluate a broad range of endpoints (e.g.,
surrogate measures of renal function, composite clinical
endpoints, quality of life, etc).
In earlier work within Kaiser Permanente Northwest
(KPNW), we conducted a cohort study restricted to
patients with stage 3 or worse CKD to predict ESRD and
the start of RRT[8]. While most patients who develop
ESRD have CKD, some do not (i.e. patients who suffer
acute kidney injury). To address this limitation of our
study, as well as the limitations of the other studies cited
above, we conducted a retrospective, nested case-control
study by sampling within the KPNW population. Our elig-
ibility criteria did not consider whether patients met labora-
tory criteria for CKD or had clinically recognized
(diagnosed) CKD, so we hope the findings on predictors of
RRT will be more pragmatic (than explanatory), and conse-
quently of interest to decision-makers in usual care settings.
Methods
Design Overview and Objective
We conducted a population-based, retrospective case-
control study of patients who presented with ESRD for
the first time (i.e., incident cases) and started RRT
w h i l et h e yw e r em e m b e r so fK P N W .O u ro b j e c t i v ew a s
to identify the strength and precision of clinician-
recorded predictors of RRT in the population-based
setting. We also calculated the population-based inci-
dence of RRT to put the odds ratios into context for
decision-makers.
Setting
We conducted the study in a health maintenance orga-
nization, Kaiser Permanente Northwest (KPNW), which
serves the Portland, Oregon and Vancouver, Washing-
ton metropolitan area. KPNW has an annual member-
ship of approximately 450,000 people. KPNW’s
electronic medical record, HealthConnect, has served as
the sole medical record at all clinics since January 1997.
KPNW as a research setting has been described in detail
elsewhere[9]. The study was reviewed and approved by
KPNW’s human subjects committee.
Identification of Cases and Controls
Patients who developed ESRD and started RRT while
they were members of KPNW were eligible to serve as
cases. Patients were identified from January 2000
through December 2004 and we identified patients who
were treated with chronic dialysis or had a kidney trans-
plant. A nephrologist (MT) confirmed the renal replace-
ment therapy and its start date by reviewing the text of
patients’ medical records.
We frequency matched controls (10 per case) on year
of RRT as well as age and sex. Controls were randomly
sampled from the source population using the case’s
index date (i.e., the same month the case patient started
RRT). Patients with a previous diagnosis or treatment
for ESRD were not eligible to serve as controls because
they were no longer at risk of developing ESRD. We
used incidence density sampling to estimate the rate
ratio from the entire cohort[10].
Index Dates and Eligibility
All patients were assigned an index date, which was
either the date they started RRT or the date they were
sampled to be a control. Risk factors for ESRD were
only measured during the baseline period (1997 through
1999) to ensure that the information could have pre-
dicted ESRD. Both case and control patients met the fol-
lowing eligibility criteria:
￿ Celebrated their 20
th birthday by the index date
(with no upper age limit).
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since January 1999 (until the index date).
￿ Maintained prescription drug coverage through
KPNW since January 1999 (until the index date).
All patients were required to be members of KPNW
during 1999; however, many patients were members as
early as 1997 and 1998. The population-based incidence
calculations used the same eligibility criteria.
Data Collection
We measured the following possible predictors of RRT
using the coded information in the electronic medical
record and the laboratory values (as noted for each
characteristic in Table 1). We divided the characteristics
into three categories: 1) demographic characteristics for
matching; 2) clinical history; 3) the most recent labora-
tory measures during the baseline period.
Sample Size Considerations
The sample size was fixed because of the retrospective
design. We observed 485 RRT starts during the period
from 2000 through 2004. The effective sample size for
multivariable analyses was reduced from 485 to 350
events because of missing data. One statistical approach
for considering the adequacy of the sample size for pre-
dictive modelling is to consider the total number of
events in relation to the number of candidate predictor
characteristics and their degrees of freedom[11]. Experts
recommend approximately 10 to 20 events per degree of
freedom. Consequently, 350 events allowed us to con-
sider 18 to 35 degrees of freedom.
Statistical Analysis
Our objective was to identify the strength and precision
of characteristics that predict RRT. Consequently, we
modeled the data using predictive methods instead of
Table 1 Baseline characteristics to predict ESRD (RRT) and how they were measured using Kaiser Permanente
Northwest data during the baseline period (1997-1999)
Characteristic Data source
Demographic characteristics for matching
Age Membership file
Sex Membership file
CLINICAL CHARACTERISTICS
Height and weight (body
mass index)
Height and weight recorded as separate fields in the medical record.
Current smoking Visit with ICD-9 code 305.1, or recorded as separate field in electronic medical record
Hypertension Visit with ICD-9 codes: 401.xx - 405.xx, or blood pressure values recorded as separate fields in the electronic medical
record (systolic ≥140 or diastolic ≥90)
Hyperlipidemia Visit with ICD-9 code 272.x, or laboratory values for total cholesterol (>199 mg/dL), low density lipoprotein (>129
mg/dL) or prescription for any statin
Diabetes Mellitus Diabetes Registry
Coronary artery disease Visit with ICD-9 codes:
410.xx - 414.xx (excluding 414.10, 414.11, 414.19), 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93,
429.4A, 429.9B, 429.9A
Congestive heart failure Visit with ICD-9 codes: 428.0, 428.9, 402.01, 402.11,402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 429.4A, 429.9B,
429.9A, 428.1
Peripheral vascular disease Visit with ICD-9 codes: 250.7x, 440.xx, 443.81, 443.9
Retinopathy Visit with ICD-9 codes:
250.5, 362.1, 362.10, 362.02A, 362.02, 362.29
CKD Visit with ICD-9 codes (referenced in the US Renal Data Systems Annual report in 2004):
016.0, 095.4, 189.0, 189.9, 223.0, 236.91, 250.4, 271.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3, 440.1, 442.1, 447.3, 572.4, 580-
588, 591, 642.1, 646.2, 753.12-753.17, 753.19, 753.2, 794.4
Kidney stones Visit with ICD-9 codes: 592.xx, 274.11
Uric acid/Gout Visit with ICD-9 code 274.0, or laboratory value for uric acid (>7.0 mg/dL)
Laboratory characteristics
Renal function Laboratory values for serum creatinine (glomerular filtration rate estimated from the four-variable MDRD Study
equation, but omitting race and assuming everyone was white)
Inflammation Laboratory values for sedimentation rate(> 20 mm/hr), C-reactive protein (> 0.9 mg/dL) (low serum albumin, wbc
count × 2 measures, wbc without bandemia or no eosinophilia, d-dimer, inflammation codes)
Urine Protein Laboratory values for proteinuria (1+ or greater, with negative leucocyte esterase)
Fasting plasma glucose Laboratory values for fasting glucose (>125 mg/dL)
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allocating patients to a characteristic wouldn’t necessa-
rily cause a higher rate of RRT. We analyzed the data
using logistic regression to calculate the odds ratios and
95% confidence intervals after controlling for matching
characteristics: age, sex, and calendar time.
To select characteristics for evaluation in the logistic
regression model, we started with clinical characteristics
that are frequently and reliably measured in routine
clinical practice (e.g., hypertension). We proceeded to
characteristics that may be less reliably measured (i.e.,
greater measurement error in the ICD-9-CM coded
electronic medical record), but which are probably
strong predictors of the outcome (e.g., history of clini-
cally recognized diabetes). We retained characteristics
in the equations if they were statistically significant
(P < 0.05).
The pattern of missing data is complicated in a retro-
spective study where collection depends on patients’ and
providers’ decisions to schedule outpatient visits and to
measure characteristics (e.g., order a laboratory test).
When investigators cannot impute missing clinical
values (because they are not missing at random), one of
the less biased methods is to analyze the subgroup of
patients with complete data for all characteristics, the
method we adopted[13].
To calculate the population-based incidence of RRT,
we added the number of person-years that members
were at risk of becoming RRT cases. We then divided
the number of RRT cases by the total person-time at
r i s ka n dc a l c u l a t e dt h ee x a c tP o i s s o n9 5 %c o n f i d e n c e
interval.
Results
Between January 2000 and December 2004, we identified
485 patients with ESRD who were treated with RRT for
the first time and met all of our eligibility criteria.
Ninety-six percent of the case patients had a serum
creatinine measurement during the baseline period
and 76% of case patients had an eGFR <60 mL/min per
1.73 m
2. The rate of RRT in the cohort from which we
sampled was 58 per 100,000 person-years (95% CI, 53 to
64) and the mean age was 66.4 years.
For most characteristics, control patients exhibited a
higher frequency of missing data. For example, body
mass index was missing for 7% of case patients, but 15%
of control patients. Characteristics more closely asso-
ciated with the diagnosis and management of kidney
disease were missing more often for control patients:
32% of control patients lacked a serum creatinine value,
b u to n l y4 %o fc a s ep a t i e n t sl a c k e das e r u mc r e a t i n i n e
value; 49% of control patients lacked a urine dipstick
measure of proteinuria, but only 27% of case patients
lacked a urine dipstick measure of proteinuria. The odds
ratios in Table 2 only reflect the crude predictive power
of characteristics (after adjusting for the matching char-
acteristics). Table 3 shows the distribution of character-
istics that contributed to the multivariable model for the
subgroup of patients with complete data and the sub-
group that we excluded from the multivariable model
b e c a u s et h e yw e r em i s s i n go n eo rm o r ec h a r a c t e r i s t i c s .
Missing serum creatinine values and urine protein
values were the main reasons for exclusion.
The final multivariable model of statistically significant
predictor characteristics included 350 case patients and
2,114 control patients (Table 4). We identified the fol-
lowing characteristics that predicted RRT: eGFR<60
mL/min per 1.73 m
2 (OR = 20.5; 95% CI, 11.2 to 37.3),
positive test for proteinuria (OR = 5.0; 95% CI, 3.5 to
7 . 1 ) ,h y p e r t e n s i o n( O R=4 . 5 ;9 5 %C I ,2 . 5t o8 . 0 ) ,g o u t /
positive test for uric acid (OR = 2.5; 95% CI, 1.8 to 3.5),
peripheral vascular disease (OR = 2.2; 95% CI, 1.4 to
3.6), congestive heart failure (OR = 2.1; 95% CI, 1.4 to
3.3), and diabetes (OR = 2.1; 95% CI, 1.5 to 2.9). We
evaluated a wide range of other characteristics that did
not improve the statistical prediction of ESRD beyond
the characteristics shown in Table 4. Although we pre-
sented sex-specific odds ratios for the final model, we
did not test for interactions by sex.
Discussion
Most observational studies that predicted ESRD using
patient characteristics enrolled patients with clinically
recognized CKD. We identified a broad range of clinical
characteristics–many of them easily measured in the pri-
mary care setting–that could help identify patients at
risk of progressing to ESRD, possibly through the devel-
opment of a prognostic risk score.
Our baseline characteristics predict RRT and which
patients lived long enough to start RRT. For example,
among KPNW patients with stage 3 or worse CKD, the
competing risk of mortality was seven times more com-
mon than RRT[8]. Although it is only one of the rele-
vant CKD-related outcomes, our model provides a first
step toward predicting which patients will start RRT in
usual care; patients with those baseline characteristics
may be priority candidates for clinical interventions that
prevent or slow the rate of progression.
T h er a t eo fE S R Di nt h ec o h o r tf r o mw h i c hw e
sampled cases and controls was markedly lower than
the overall US rate, in part because our HMO and the
metropolitan area that it serves under-represented
higher-risk racial and ethnic groups compared with the
entire US. Although the HMO did not collect race and
ethnicity data consistently during our study period,
unpublished surveys of our members have suggested
that most (88%) were white, non-Hispanic. Even among
white residents, the Portland metropolitan area ranked
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2000 through 2004; Table 1 explains how characteristics were measured
Characteristic % or mean
cases
(n = 485)
%o r
mean
controls
(n = 4,850)
Odds Ratio*
(95% CI)
Demographic matching
Age (mean, continuous) 64.4 64.4 (matched)
Sex (%, male is referent) 45.6 45.6 (matched)
Clinical
BMI (%)
<30 (referent) 51.1 52.2
≥30 41.7 32.7 1.28 (1.06 to1.56)
Unknown 7.2 15.2
Current smoking (%)
Nonsmoker (referent) 63.9 54.0
Smoker 32.8 33.2 0.82 (0.67 to 1.00)
Unknown 3.3 12.8
Hypertension (%) 90.9 53.4 11.15 (8.03 to 15.48)
Hyperlipidemia or statin (%) 62.7 42.5 2.36 (1.93 to 2.87)
Diabetes (%) 54.0 15.9 6.67 (5.45 to 8.15)
Coronary artery disease (%) 19.8 7.9 3.07 (2.38 to 3.98)
Congestive heart failure (%) 25.0 4.4 8.25 (6.35 to 10.72)
Peripheral vascular disease (%) 23.1 3.8 8.18 (6.27 to 10.67)
Retinopathy (%) 18.1 1.1 19.41 (13.63 to 27.62)
Kidney disease (%) 53.0 1.9 61.62 (46.61 to 81.46)
Acute renal failure (%) 8.0 0.4 24.78 (13.90 to 44.18)
Kidney stone (%) 2.9 2.1 1.40 (0.79 to 2.47)
Gout/Uric acid (%) 62.7 18.3 8.20 (6.68 to 10.06)
ACEI/ARB use (%) 65.0 19.8 8.80 (7.11 to 10.89)
Laboratory
Renal function (GFR, %)
90+ (referent) 6.4 17.8
60-89 13.8 38.6 1.73 (1.10 to 2.70)
<60 75.9 11.2 50.52 (32.55 to 78.42)
30-59 (Stage 3) 35.9 10.6 24.96 (15.83 to 39.36)
<30 (Stage 4 or 5) 40.0 0.6 533.51 (292.57 to 972.89)
Unknown 3.9 32.4
Inflammation (%)
No (referent) 65.0 52.7
Yes 24.7 11.9 1.74 (1.38 to 2.19)
Unknown 10.3 35.4
Urine Protein (%)
No (referent) 28.9 47.1
Yes 44.1 4.2 18.89 (14.31 to 24.73)
Unknown 27.0 48.7
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th percentile) based on its age- and sex-adjusted
rate of ESRD (compared with the largest 25 metropoli-
tan statistical areas in the US)[14]. Oregon and
Washington belong to Network 16, a collection of five
Northwestern states tracked by the US Renal Data Sys-
tems (USRDS) Annual Data Report. Network 16 states
experienced the lowest age- and sex-adjusted rate of dia-
lysis of the 18 Networks tracked by USRDS[14].
We need to consider biases that might have distorted
the size of the odds ratios in this case-control study. To
the extent that our final model omitted other important
predictors of ESRD, the odds ratios reported here may
appear larger than they would in a more complete
model. Many of the characteristics were not measured
systematically, especially among control patients, as
revealed by the pattern of missing data: The ratio of
controls to cases drops from 10 to 1 to 6 to 1 after
excluding patients with missing data. Physicians ordered
certain laboratory tests in part because other clinical
signs raised their suspicion of CKD. For example, uni-
versal screening for proteinuria at KPNW would prob-
ably exhibit a lower odds ratio than the estimate
reported in our case-control study because higher risk
patients would not be tested preferentially. Our odds
ratios reflect the combination of the characteristics’
intrinsic predictive values and the physicians’ insights
for ordering the tests or recording the diagnoses. But
reducing the measurement error could also strengthen
the predictive power of other characteristics that were
measured more systematically. For example, we only
Table 2 Baseline characteristics (1999 or earlier) evaluated for the prediction of ESRD (RRT) that occurred between
2000 through 2004; Table 1 explains how characteristics were measured (Continued)
Impaired fasting plasma glucose (%)
No (referent) 32.4 35.2
Yes 22.5 6.8 3.64 (2.77 to 4.78)
Unknown 45.2 58.0
* Odds ratios measure the crude or unadjusted predictions except that all characteristics are adjusted for the matching characteristics: age, sex, and year.
Table 3 Baseline characteristics (1999 or earlier) evaluated for the prediction of ESRD (RRT) that occurred between
2000 through 2004 according to whether patients had complete data for the logistic regression model (shown in
Table 4) and the subgroup that we excluded because they were missing one or more characteristics
Characteristic % or mean % or mean % or mean % or mean
Complete cases (n = 2,464) Deleted from model (n = 2,871)
Cases (n = 350) Controls (n = 2,114) Cases
(n = 135)
Controls (n = 2,736)
Demographic matching
Age (mean, continuous) 64.3 68.7 64.9 61.1
Sex (%, male is referent) 47.1 47.7 41.5 43.9
Clinical
Hypertension (%) 94.9 65.42 80.7 44.2
Diabetes (%) 52.3 23.0 58.5 10.4
Congestive heart failure (%) 26.9 7.4 20.0 2.1
Peripheral vascular disease (%) 22.3 5.8 25.2 2.3
Gout/Uric acid (%) 72.3 30.7 37.8 8.7
Laboratory
Renal function (GFR, %)
90+ (referent) 4.9 25.2 10.4 12.0
60-89 12.6 57.7 17.0 23.8
<60 82.6 17.2 58.5 6.7
Unknown 14.1 57.5
Urine Protein (%)
No (referent) 39.1 90.9 2.26 13.3
Yes 60.9 9.1 0.74 0.4
Unknown 97.0 86.3
Johnson et al. BMC Nephrology 2011, 12:17
http://www.biomedcentral.com/1471-2369/12/17
Page 6 of 8required one serum creatinine value at baseline to esti-
mate patients’ GFR, which inevitably increases the prob-
ability of false-positive classifications attributable to acute
renal disease; a second serum creatinine repeated 90 or
more days after the initial serum creatinine would reduce
measurement error in our classification of GFR and
increase the odds ratio for predicting RRT. Perneger and
colleagues provide a more thorough review of potential
biases in conducting epidemiologic studies of ESRD[15].
Our retrospectively measured clinical characteristics
were largely consistent with the size of estimates from
the most similar cohort study, conducted in patients
from Kaiser Permanente Northern California. For exam-
ple, our adjusted odds ratio for diabetes (OR = 2.1) was
similar to the adjusted hazard ratio (HR = 2.5) reported
by Hsu and colleagues even though their final model
included many additional predictors and they followed
patients five times longer than we did[4]. Our odds ratio
for hypertension (OR = 4.5) was larger than the hazard
ratio (HR = 2.9) for severe (stage 2) hypertension
reported by Hsu and colleagues.
Conclusion
The clinical characteristics needed for prediction–for
example, to develop a population-based, prognostic risk
score–were often documented during routine care years
before patients developedE S R Da n dr e q u i r e dR R T .
Nephrologists have long recognized the prognostic value
of many of the patient characteristics used in this case-
control study. What’s important for intervention in pri-
mary care is that most of the characteristics are readily
available through patient history and the outpatient
medical record. Future studies should develop prognos-
tic risk scores to predict the absolute risk of developing
ESRD and starting RRT, which will require a more sys-
temic collection of laboratory findings for eGFR and
proteinuria.
Acknowledgements
Sanofi-Aventis sponsored the study through a contract to Kaiser
Permanente’s Center for Health Research. The contract protected the
investigators’ right to publish the findings in the journal of their choice and
the Kaiser Permanente investigators were under no obligation to accept the
sponsor’s comments on the manuscript, which does not evaluate any
products. All authors were employees of Kaiser Permanente except Dr
Juhaeri Juhaeri who was employed by Sanofi-Aventis at the time the study
was conducted. Dr Juhaeri was involved in the study’s conceptualization
and provided critical revisions to the manuscript, but Dr Juhaeri, as a
representative of the sponsor, had no role in deciding whether to submit
the manuscript for publication. Dr Eric Johnson wrote the manuscript
without the assistance of medical writers. We wish to thank Ms Mara Kalter
and Ms Amanda Petrik for their support in coordinating the study.
Author details
1The Center for Health Research, Kaiser Permanente Northwest, Portland,
Oregon, USA.
2Department of Nephrology, Kaiser Permanente Northwest,
Portland, Oregon, USA.
3Sanofi-Aventis, Bridgewater, New Jersey, USA.
Authors’ contributions
EJ, DS, MT and JJ conceptualized the study and its objective. EJ and DS
designed the study. MT confirmed cases of RRT by reviewing medical
records. DS and MT provided clinical expertise on measuring and selecting
the baseline predictor characteristics. XY extracted the data from the HMO’s
databases, analyzed the data statistically and contributed to the data’s
interpretation. EJ wrote the manuscript; DS, MT, XY and JJ revised the
manuscript critically. All authors read and approved the manuscript.
Competing interests
The authors have no competing financial interest to declare because the
study evaluates the natural history of chronic kidney disease and does not
evaluate any products.
Received: 4 January 2011 Accepted: 5 May 2011 Published: 5 May 2011
Table 4 Baseline characteristics (1997-1999) evaluated for
the prediction of ESRD (RRT) that occurred between 2000
through 2004 for 350 cases and 2,114 controls.
Characteristic Odds Ratio
(95% CI)
men
185 cases
Odds Ratio
(95% CI)
women
165 cases
Odds Ratio*
(95% CI)
men and
women
350 cases
Demographic matching
Age (matched)
Sex (matched)
Year (matched)
Clinical
Hypertension 3.62
(1.65 to
7.94)
5.86
(2.47 to
13.92)
4.51
(2.53 to 8.02)
Diabetes 2.37
(1.49 to
3.77)
1.84
(1.13 to 2.98)
2.08
(1.49 to 2.90)
Congestive heart
failure
2.07
(1.15 to
3.70)
2.20
(1.15 to 4.21)
2.12
(1.38 to 3.27)
Peripheral vascular
disease
1.73
(0.92 to
3.27)
2.97
(1.44 to 6.12)
2.20
(1.37 to 3.55)
Gout/Uric acid 2.66
(1.62 to
4.36)
2.43
(1.50 to 3.93)
2.51
(1.78 to 3.54)
Laboratory
Renal function (GFR)
90+ (referent)
60-89 1.17
(0.53 to
2.60)
2.72
(1.01 to 7.35)
1.68
(0.91 to 3.12)
<60 15.67
(7.27 to
33.80)
29.84
(11.16 to
79.79)
20.47
(11.22 to 37.34)
Urine Protein
No (referent)
Yes 5.13
(3.22 to
8.16)
4.88
2.82 to 8.47
4.99
(3.51 to 7.10)
* Odds ratios measure the multivariable or adjusted predictions, including
adjustment for the matching characteristics: age, sex, and year.
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